<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lombardi A</submitter><funding>NIDDK NIH HHS</funding><pagination>15823</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5696524</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(1)</volume><pubmed_abstract>Sirolimus (rapamycin) is an immunosuppressive drug used in transplantation. One of its major side effects is the increased risk of diabetes mellitus; however, the exact mechanisms underlying such association have not been elucidated. Here we show that sirolimus impairs glucose-stimulated insulin secretion both in human and murine pancreatic islets and in clonal β cells in a dose- and time-dependent manner. Importantly, we demonstrate that sirolimus markedly depletes calcium (Ca2+) content in the endoplasmic reticulum and significantly decreases glucose-stimulated mitochondrial Ca2+ uptake. Crucially, the reduced mitochondrial Ca2+ uptake is mirrored by a significant impairment in mitochondrial respiration. Taken together, our findings indicate that sirolimus causes depletion of intracellular Ca2+ stores and alters mitochondrial fitness, eventually leading to decreased insulin release. Our results provide a novel molecular mechanism underlying the increased incidence of diabetes mellitus in patients treated with this drug.</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.</pubmed_title><pmcid>PMC5696524</pmcid><funding_grant_id>K99 DK107895</funding_grant_id><funding_grant_id>P30 DK020541</funding_grant_id><funding_grant_id>R00 DK107895</funding_grant_id><pubmed_authors>Du XL</pubmed_authors><pubmed_authors>Trimarco B</pubmed_authors><pubmed_authors>Santulli G</pubmed_authors><pubmed_authors>Lombardi A</pubmed_authors><pubmed_authors>Mauro M</pubmed_authors><pubmed_authors>Sorriento D</pubmed_authors><pubmed_authors>Gambardella J</pubmed_authors><pubmed_authors>Iaccarino G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.</name><description>Sirolimus (rapamycin) is an immunosuppressive drug used in transplantation. One of its major side effects is the increased risk of diabetes mellitus; however, the exact mechanisms underlying such association have not been elucidated. Here we show that sirolimus impairs glucose-stimulated insulin secretion both in human and murine pancreatic islets and in clonal β cells in a dose- and time-dependent manner. Importantly, we demonstrate that sirolimus markedly depletes calcium (Ca2+) content in the endoplasmic reticulum and significantly decreases glucose-stimulated mitochondrial Ca2+ uptake. Crucially, the reduced mitochondrial Ca2+ uptake is mirrored by a significant impairment in mitochondrial respiration. Taken together, our findings indicate that sirolimus causes depletion of intracellular Ca2+ stores and alters mitochondrial fitness, eventually leading to decreased insulin release. Our results provide a novel molecular mechanism underlying the increased incidence of diabetes mellitus in patients treated with this drug.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Nov</publication><modification>2024-11-09T23:23:55.122Z</modification><creation>2019-03-27T03:02:34Z</creation></dates><accession>S-EPMC5696524</accession><cross_references><pubmed>29158477</pubmed><doi>10.1038/s41598-017-15283-y</doi></cross_references></HashMap>